ASMANEX Inhalation Powder Recalled Due to Defective Container
Organon LLC is recalling 2,551 units of ASMANEX Twisthaler mometasone furoate inhalation powder nationwide due to defective containers. Affected lot X024051 expires April 25, 2025.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recall for a container defect with no reported illnesses or injuries. The defect relates to packaging integrity rather than the drug formulation itself, and the recall is voluntary and precautionary.
Plain-English summary
ASMANEX Twisthaler (mometasone furoate) inhalation powder, 220 micrograms per actuation, is being recalled due to defective containers. Organon LLC initiated this voluntary recall on May 28, 2024, after identifying the issue. The recalled product includes lot number X024051 with an expiration date of April 25, 2025.
The recall affects 2,551 units distributed nationwide in the United States. Patients using ASMANEX from the affected lot should consult their healthcare provider or pharmacist about their medication.
The FDA classified this as a Class III recall. Organon LLC, a subsidiary of Organon & Co., manufactures the product in Singapore. The company notified customers by letter.
The recalled product
- Product
- ASMANEX (MOMETASONE FUROATE)
- Brand
- ASMANEX
- Manufacturer
- Organon Llc
- Category
- Drug — Inhalation Medication
- Hazard
- defective-container
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: X024051
- Exp 04/25/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ASMANEX
- ModerateAsmanex (Mometasone Furoate) Recalled Due to Defective Container
FDA (Drugs) · 2024-06-19
- ModerateFDA recalls Asmanex asthma inhalation powder for improper storage conditions
FDA (Drugs) · 2024-01-03
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27